Remove Engineering Remove Molecular Biology Remove RNA
article thumbnail

Turning science into business: Merging AI and RNA

Drug Discovery World

DDW’s Diana Spencer speaks to Raphael Townshend PhD, Founder and CEO of Atomic AI, about the company’s successes so far, plans for the future and the unique approach of combining RNA structural biology and AI models. DS: How is Atomic AI “unlocking the next generation of RNA drug discovery”? What is unique about your engine?

RNA 130
article thumbnail

Using AI to design RNA-based medicines

Drug Discovery World

US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. As tech experts call for improved regulation and a halt to the development of AI, we take a look at how one company, Atomic AI, is using it to develop RNA-targeting treatments for a range of diseases.

RNA 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

$35 million to advance AI-driven RNA structure platform

Drug Discovery World

Atomic AI, a biotechnology company fusing machine learning with structural biology to unlock RNA drug discovery, launched today with a $35 million Series A round. Atomic AI is oriented at the cutting edge of AI, RNA, and structural biology.

RNA 130
article thumbnail

smartRNA project joins BII Bio Studio programme

Drug Discovery World

A project focused on developing a small RNA-based platform technology for treating monogenic diseases, smartRNA, has joined the BioInnovation Institute’s (BII) Bio Studio programme. The technology has platform potential, as it leverages a universal small RNA pathway to target generic mRNA features.

RNA 130
article thumbnail

DDW Cancer Research Summit: Industry experts join the panel

Drug Discovery World

The main presentations will be followed by a panel discussion on how these new approaches – e.g., engineered proteins, antibodies, micro RNA, nanocarriers, antibody drug conjugates – can help address unmet need in oncology. He joined Taconic Biosciences in 2014 has been the Vice President of Commercial Products since 2017.

Research 130
article thumbnail

Enhancing gene therapy with Circio

Drug Target Review

What are the key findings of Circio’s in vivo proof-of-concept for its circVec circular RNA platform technology compared to conventional mRNA-based expression with DNA vectors? Circular RNA (circRNA) has two major advantages versus mRNA in a vector-expression context.

article thumbnail

Synthetic Origins

Codon

A gene encoding green fluorescent protein was placed alongside one of the three promoters, and as the engineered cells cycled from one gene to the next, they blinked between green—dark—green—dark. These papers became the standard-bearers for a new scientific field: synthetic biology. Elowitz: It’s a mix.

RNA 57